| Literature DB >> 34217314 |
Cho Naing1,2, Siew Tung Wong3, Htar Htar Aung3.
Abstract
BACKGROUND: Malaria is still a major public health problem in sub-Saharan Africa and South-east Asia. The clinical presentations of malaria infection vary from a mild febrile illness to life-threatening severe malaria. Toll like receptors (TLRs) are postulated to be involved in the innate immune responses to malaria. Individual studies showed inconclusive findings. This study aimed to assess the role of TLR4 (D299G, T399I) and TLR9 (T1237C, T1486C) in severity or susceptibility of malaria by meta-analysis of data from eligible studies.Entities:
Keywords: Malaria; Meta-analysis; Polymorphisms; Severity; Susceptibility; Toll-like receptor
Year: 2021 PMID: 34217314 PMCID: PMC8255014 DOI: 10.1186/s12936-021-03836-6
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Study selection process
Characteristics of the included studies
| Author, year [Ref] | SNP | Country | Setting | Age group in cases,yr | Male % in cases | Cases | Controls | Genotyping method | Consistent with HWE |
|---|---|---|---|---|---|---|---|---|---|
| Mockenhaupt, 2006 [ | TLR4-A299G, T399I TLR9 T-1237C, T1486C | Ghana | H | Children | 46.6 | 290 | UM: 290 Healthy: 290 | allele-specific PCR and PCR-RT | Yes |
| Leoratti, 2008 [ | TLR4 D299G TLR9 T1237C, T1486C | Brazil | H | md 29 | 86 | 230 | 74 | PCR–RFLP | Yes |
| Sam-Agudu, 2010 [ | TLR4-A299G, T399I TLR9-T1486C, T1237C | Uganda | H | 6.2 (2.4) | 63.1 | Cases (SM): 65 | Controls (UM: 52 | PCR and LDR-FMA | Yes |
Zakeri, 2011 [ | TLR4 D299G, T399I TLR9 T1486C, T1237C | Iran | HCs | md 28 | 65.6 | P. falciparum infected: 320 | Healthy control: 320 | PCR–RFLP | Yes |
| Esposito, 2012 [ | TLR4 A299G (rs4986790) TLR9 T1486C (rs187084), T1237C (rs5743836) | Burundi | H | Children | 57.5 | 602 | 337 | Taqman | Yes |
Munde, 2012 [ | TLR9 T1237C | Kenya | H | Children | 47.8 | SM: 138 | UM: 163 | TaqMan | Yes |
Sawian, 2012 [ | TLR4 A299G TLR9 T1237C, T1486C | India | H | md: 26.2 (R2-58) | SM: 136 | Controls (UM: 53 | PCR–RFLP | No | |
Kar, 2015 [ | TLR4 D299G TLR9 T1237C, T1486C | India | H | SM: 38.0 (25.0–53.7) UM: 38.0 (24.2–55.0) | 58% | 200 | 200 | PCR–RFLP | Yes (D299G) No (T1237C and T1486C) |
| Iwalokun, 2015 [ | TLR4 A299G, T399I | Nigeria | H | Children | 62.1 | 182 | 97 | PCR–RFLP | Yes |
| Costa, 2017 [ | TLR4 A299G (rs4986790), T399I (rs4986791) TLR9-T1237C (rs187084), T1486C (rs5743836) | Brazil | 37 (19 ± 53) | 61.5 | Healthy group: 274 | PCR–RFLP | Yes (A299G, T399I, T1237C) No (T1486C) | ||
| Rani, 2018 [ | TLR4 A299G | Pakistan | H | 22.7 ± 13.6 | 53.5 | 228 (SM: 89, UM: 139) | 226 | Allele-specific PCR | No |
H hospital, HC Primary Health Centre, HWE Hardy–Weinberg equilibrium, LDR-FMA ligase detection reaction-fluorescent microsphere assay, md median, PCR–RFLP polymerase chain reaction-restriction fragment length polymorphism fragment length, PCR-RT real-time PCR, R range, SM severe malaria/complicated malaria/cerebral malaria, SNP single nucleotide polymorphism, TaqMan TaqMan allelic discrimination/SNP assay, UM uncomplicated malaria/mild malaria, Yes/No controls are/are not consistent with HWE
Fig. 2Geographic distribution of the included studies
Fig. 3Forest plot for TLR 9 (T1486C) in severe malaria
Associations for the risk of severe malaria
| Polymorphisms | Variants | Number of studies included | Total cases/controls | Genetic model | Effect size, OR (95%CI) | Model |
|---|---|---|---|---|---|---|
| TLR 9 | T1486C | 5 | 1380/2378 | Allele | ||
| 660/1189 | Dominant | 1.29 (0.84–1.98) | R | |||
| 660/1189 | Recessive | 1.27 (0.9–1.79) | ||||
| 325/697 | Homozygous | |||||
| 585/1091 | Heterozygous | 1.26 (0.73–2.16) | R | |||
| TLR 9 | T1237C | 6 | 1606/2720 | Allele | 1.01 (0.81–1.27) | R |
| 803/1350 | Dominant | 1.32 (0.86–2.03) | R | |||
| 803/1350 | Recessive | 0.71 (0.36–1.42) | R | |||
| 442/854 | Homozygous | 0.87 (0.45–1.7) | R | |||
| 722/1145 | Heterozygous | 1.57 (0.86–2.86) | R | |||
| TLR 4 | T399I | 2 | 202/152 | Allele | 1.03 (0.47–2.28) | F |
| 104/79 | Dominant | 1.05 (0.43–2.8) | F | |||
| 104/79 | Recessive | 0.73 (0.1–5.31) | F | |||
| 85/57 | Homozygous | 0.74 (0.1–5.41) | F | |||
| 102/77 | Heterozygous | 1.11 (0.43–2.91) | F | |||
| TLR 4 | D299G | 7 | 1463/2936 | Allele | 1.16 (0.93–1.44) | F |
| 773/1495 | Dominant | 1.1 (0.87–1.4) | F | |||
| 773/1495 | Recessive | 0.99 (0.78–1.26) | F | |||
| 625/1207 | Homozygous | 1.29 (0.65–2.55) | F | |||
| 759/1478 | Heterozygous | 1.08 (0.84–1.37) | F |
CI confidence interval, F fixed-effect model, OR odds ratio, R random-effects model
Significant result is in bold
Fig. 4Forest plot for TLR 9 (T1237C) in severe malaria
Associations for the risk of susceptibility to malaria
| Polymorphisms | Variants | Number of studies included | Cases/controls | Genetic model | Effect size, OR (95% CI) | Model |
|---|---|---|---|---|---|---|
| TLR 9 | T1486C | 5 | 3472/2610 | Allele | 1.03 (0.91–1.16) | F |
| 1740/1166 | Dominant | 1.07 (0.78–1.47) | F | |||
| 1740/1166 | Recessive | 0.93 (0.68–1.27) | F | |||
| 801/533 | Homozygous | 0.85 (0.5–1.43) | R | |||
| 1566/1018 | Heterozygous | 1.17 (0.78–1.78) | R | |||
| TLR 9 | T1237C | 5 | 2867/2217 | Allele | 0.97 (0.84–1.12) | F |
| 1735/1387 | Dominant | 0.87 (0.52–1.45) | R | |||
| 1735/1387 | Recessive | 1.53 (0.86–2.75) | R | |||
| 1225/859 | Homozygous | 1.28 (0.97–1.68) | R | |||
| 1537/1173 | Heterozygous | 0.82(0.49–1.4) | R | |||
| TLR 4 | T399I | 4 | 1716/1400 | Allele | 0.95 (0.69–1.31) | F |
| 861/707 | Dominant | 0.99 (0.71–1.39) | F | |||
| 861/707 | Recessive | 1.03 (0.73–1.46) | F | |||
| 776/634 | Homozygous | 0.54 (0.17–1.69) | F | |||
| 826/700 | Heterozygous | 1.13 (0.8–1.6) | F | |||
| TLR 4 | D299G | 7 | 3776/2847 | Allele | 1.05 (0.86–1.29) | F |
| 1959/1576 | Dominant | 1.11 (0.9–1.36) | F | |||
| 684/1356 | Recessive | 0.83 (0.66–1.05) | F | |||
| 545/1092 | Homozygous | 0.95 (0.51–1.79) | F | |||
| 672/1341 | Heterozygous | 1.08 (0.87–1.34) | F |
F fixed effect model, R random effects model